Jiang JJ - Search Results

1

Population pharmacokinetics of naringin in total flavonoids of Drynaria fortunei (Kunze) J. Sm. in Chinese women with primary osteoporosis.

Wang JN, Jiang JJ, Xie YM, Wei X, Li JP, Duan JL, Xiong X. Wang JN, et al. Among authors: jiang jj. Chin J Integr Med. 2012 Dec;18(12):925-33. doi: 10.1007/s11655-012-1296-0. Epub 2012 Dec 13. Chin J Integr Med. 2012. PMID: 23239001

2

[Post-marketing re-evaluation about usage and dosage of Chinese medicine based on human population pharmacokinetics].

Jiang J, Xie Y. Jiang J, et al. Zhongguo Zhong Yao Za Zhi. 2011 Oct;36(20):2811-2. Zhongguo Zhong Yao Za Zhi. 2011. PMID: 22292372 Chinese.

3

[Key elements of design about PPK of Chinese medicine after marketing].

Wang J, Jiang J, Xie Y. Wang J, et al. Zhongguo Zhong Yao Za Zhi. 2011 Oct;36(20):2871-3. Zhongguo Zhong Yao Za Zhi. 2011. PMID: 22292388 Chinese.

4

[Discussion on establishment of quality control system for intensive hospital monitoring on traditional Chinese medicine injections].

Jiang JJ, Xie YM. Jiang JJ, et al. Zhongguo Zhong Yao Za Zhi. 2012 Sep;37(18):2689-91. Zhongguo Zhong Yao Za Zhi. 2012. PMID: 23285909 Chinese.

5

Development and validation of a sensitive liquid chromatography-tandem mass spectrometry method for the determination of naringin and its metabolite, naringenin, in human plasma.

Xiong X, Jiang J, Duan J, Xie Y, Wang J, Zhai S. Xiong X, et al. J Chromatogr Sci. 2014 Aug;52(7):654-60. doi: 10.1093/chromsci/bmt095. Epub 2013 Jul 9. J Chromatogr Sci. 2014. PMID: 23839803

6

[Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].

Xie YM, Liao X, Zhao YB, Li MQ, Zhang YL, Ma R, Xian SX, Liu J, Li SY, Wen ZH, Yang ZQ, Zou JD, Sun HS, He Y, Li XL, Jiang JJ, Wang ZF, Li YY, Wang LX, Chang YP, Yang W, Zhang W. Xie YM, et al. Among authors: jiang jj. Zhongguo Zhong Yao Za Zhi. 2013 Sep;38(18):2919-24. Zhongguo Zhong Yao Za Zhi. 2013. PMID: 24471304 Chinese.

7

[Expert consensus post-marketing evaluation scheme to detect immunotoxicity of Chinese medicine in clinical populations (draft version for comments)].

Xie YM, Zhao YB, Jiang JJ, Chang YP, Zhang W, Shen H, Lu PF. Xie YM, et al. Among authors: jiang jj. Zhongguo Zhong Yao Za Zhi. 2013 Sep;38(18):2933-6. Zhongguo Zhong Yao Za Zhi. 2013. PMID: 24471307 Chinese.

8

[Expert consensus on population pharmacokinetics of Chinese medicine ( draft version for comments)].

Xie YM, Wang JN, He FY, Jiang JJ, Xiong X. Xie YM, et al. Among authors: jiang jj. Zhongguo Zhong Yao Za Zhi. 2013 Sep;38(18):2937-42. Zhongguo Zhong Yao Za Zhi. 2013. PMID: 24471308 Chinese.

9

[Spontaneous reportintg system data based on shuxuetong injection adverse reactions signal warning analysis].

Jiang JJ, Xiang YY, Xie YM, Shen H. Jiang JJ, et al. Zhongguo Zhong Yao Za Zhi. 2013 Sep;38(18):2994-7. Zhongguo Zhong Yao Za Zhi. 2013. PMID: 24471318 Chinese.

10

[Based on hospital information system data, analysis of effects of different doses of shenmai injection on renal function].

Jiang JJ, Tang H, Xie YM, Yang H, Zhuang Y. Jiang JJ, et al. Zhongguo Zhong Yao Za Zhi. 2013 Sep;38(18):3060-7. Zhongguo Zhong Yao Za Zhi. 2013. PMID: 24471330 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

731 results

Search Page